The treatment of non-Hodgkin lymphomas has benefited enormously from the introduction of monoclonal antibody-based therapies. However, the efficacy of these treatments varies with lymphoma subtypes and typically decreases with subsequent relapses. Here, we report on 
Introduction
B-cell lymphomas represent approximately 90% of all non-Hodgkin's lymphomas in western countries.
1,2 They include diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia and Burkitt's lymphoma (BL). 2 The development of monoclonal antibodies, such as rituximab, to target specific markers on B lymphoma cells has completely revolutionized treatment and improved patient prognosis. 3, 4 Rituximab adheres to CD20 and orchestrates cell death via complement-and antibody-mediated cellular cytotoxicity and by sensitizing malignant B-cells to concomitant chemotherapy. 5, 6 Current treatment regimens now generally include combinations of conventional cancer treatments, typically including cytostatic drugs, and monoclonal antibodies directed against molecules expressed on the surface of lymphoma cells. 7, 8 Unfortunately, however, not all lymphoma types are sensitive to antibody treatment and the ones that are frequently become resistant. 9 For this reason, alternative antibody molecules are under development. This includes antibodies coupled to various oncolytic substances such as toxins, radionuclides and cytotoxic drugs. 10 These armed antibodies are substantially more active than their classical counterparts but so far do not represent a curative treatment.
Antigen-armed antibodies (AgAbs) are antibodies fused to antigens first described by Lunde et al, who demonstrated that antigen could be delivered to antigen-presenting cells (APCs),
including DCs and B-cells, using antibody as a targeting vehicle and that this resulted in activation of antigen-specific T cells, both in vitro and in vivo. 11, 12 Diverse antigens could be used in AgAbs, including the hemagglutinin protein of influenza virus, hen egg lysozyme, and ovalbumin. 13 Therefore, AgAbs represent a promising vaccine strategy for viral and bacterial pathogens such as Epstein-Barr virus (EBV), HIV and pneumonic plague [14] [15] [16] [17] [18] [19] , as well as cancer vaccines using specific tumor antigens, such as MAGE-A3. 20 Most studies . 19 LCLs express DEC-205 at similar levels to DCs and efficiently present
For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From targeted EBV nuclear antigen 1 (EBNA1) and EBV-latent membrane protein 1 (LMP1) to EBNA1-and LMP1-specific CD4+, and to a lesser extent, CD8+ T cell clones in vitro 19 .
The effectiveness of the AgAb strategy in inducing a T cell response against the viral antigen it carries could be adapted to specifically target B lymphoma cells. This requires an antibody that efficiently targets B-cell lymphoma cells and induces presentation of the antigen it carries at the surface of the tumor cells to elicit a specific immune response. We have generated
AgAbs that target various B-cell receptors and contain immunodominant T cell epitopes from multiple EBV proteins. EBV is a ubiquitous gammaherpesvirus for which more than 90% of the adult human population is seropositive. 21 By choosing epitopes from a virus such as EBV,
we can ensure that the vast majority of the patient population will have circulating memory T cells that are specific to the epitopes contained in the AgAbs. In this study we present our findings that LCLs and various BL cell lines effectively present antigen to cytotoxic CD4+ T cells following AgAb treatment targeted to the CD19, CD20, CD21 and CD22 B-cell receptors. This study demonstrates the potential of the AgAb treatment strategy in the treatment of B-cell lymphomas.
For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From by density gradient centrifugation. Cells were grown in RPMI medium supplemented with 10% fetal calf serum. EBV-specific CD4+ T-cell clones were isolated from EBV-seropositive donors and cultivated as described previously 23, 26 . Ethical approval to use sera from voluntary donors was obtained from the Ethikkommission of the Medizinische Fakultät Heidelberg (S-36/2011).
Materials and Methods

Primary cells and cell lines
Plasmids
Generation and expression of the plasmids containing the heavy-and light-chain genes of anti-human CD19-, CD20-, CD21-and CD22-specific antibodies with and without EBV epitopes as well as of the different controls is described in the Supplemental Methods, together with Western blot and flow cytometry.
T-cell antigen recognition assays
Antigen presentation by LCLs and B lymphoma cell lines was tested in T-cell antigen recognition assays, as described. 23 Briefly, B-cells (5x10 4 ) were incubated with medium only, peptides or antibodies for 24 h. These were subsequently mixed for 18 h with autologous EBV-specific CD4+ T cell clones (1x10 5 ). Interferon-gamma (IFN-γ) released into the supernatants was quantified by enzyme-linked immunosorbent assay (ELISA) system (R&D Systems).
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Cytotoxicity Assay
The ability of antigen-specific T cells to kill their targets was determined in a 4 h Chromium-
(
51 Cr) release assay, as described. 27 Target cells (1.5x10 5 ) were treated for 24 h with peptide or AgAbs, or were untreated, and subsequently labeled with 51 Cr (30μCi). Each treatment group was divided into a negative control (medium only, spontaneous release), a positive control (treatment with 1% Triton-X 100, maximum release) and several test reactions containing increasing effector T cell to target cell (E:T) ratios. Effector T cells (EBV antigen-specific T cell clones) were added at E:T ratios ranging from 1:1 to 50:1.
Supernatants were harvested after 4 h and cell lysis was determined by 51 Cr release, as measured by a Microbeta Trilux liquid scintillation counter (PerkinElmer). The percentage of specific release was calculated as follows: (experimental release -spontaneous release) /
(maximum release -spontaneous release) x100. All experimental groups were performed in triplicate.
Generation and expansion of 5H11-specific T cell clones ex vivo
PBMCs were isolated from blood of an EBV-positive donor whose HLA class II genotype was compatible with the LCLs used as antigen-presenting cells using density gradient centrifugation. 5x10^6 PBMCs in 2mL of AIM-V medium (Life Technologies) without IL-2 were pulsed with 1.3ng of CD21-specifc 5H11-coupled antibody. After 2 weeks, 5x10^6
fresh PBMCs isolated from the same donor were pulsed with 1.3ng of aCD21-5H11 antibody, irradiated (40Gy) and mixed with the previously isolated PBMCs in AIM-V medium with 10U/mL IL-2. The same procedure was repeated biweekly. After the 7 th stimulation round, limiting dilution cloning was performed as described by seeding 1, 3 or 6 cells/well and using haplotype matched irradiated (80Gy) LCLs loaded with 5H11 peptide as stimulators. 14, 17 Outgrowing T cell clones were expanded to perform T cell assays with the aCD21-5H11
antibody.
Results
Recombinant AgAbs target B-cell surface receptors on LCLs
We generated a panel of eukaryotic expression plasmids encoding the heavy and light chains of mouse IgG2a antibodies directed against the B-cell surface receptors CD19, CD20, CD21 and CD22 ( Figure 1A) . In order to produce AgAbs ( Figure 1B) , various EBV epitopes were introduced into the C H 2 region of the antibody heavy chains ( Table 1 For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From
LCLs efficiently present antigen targeted by AgAbs to CD4+ T cells
In order to determine the ability of LCLs to present antigen targeted by AgAbs, T cell response assays were performed using CD4+ T cell clones specific to epitopes from various EBV proteins ( Figure 2 , Table 1 ).
We investigated the 5H11 and 3H10 epitopes of EBNA3C, the B9 epitope of EBNA3B and the 5A11 epitope of EBNA2 (Table 1) . (Fig. 2Ci and   2D ). However, this response was highly specific, as matched T cells that recognize the M1 influenza protein did not react with LCLs treated with the α CD21-B9 AgAb (Fig. 2Cii) .
AgAbs directed against CD19, CD20 and CD22 demonstrated similar responses for EBNA3C 3H10-, EBNA3C 5H11-and EBNA3B B9-specific T cell clones (these antibodies were not studied for EBNA2-specific T cell clones).
Next, we investigated whether CD4+ T cells activated by AgAbs containing the EBNA3C
3H10 epitope were capable of killing the LCL target cells (Fig. 3) . We used 51 Cr-release killing assays to determine cytotoxic activity. Target LCLs (1.5x10 5 ) were loaded with 1μg 3H10 peptide, 10ng or 1ng 3H10 AgAbs, or 10ng antibodies without epitope, or left untreated (medium only) and mixed with effector T cells. The percentage of total cell lysis was determined as an indicator of the ability of the T cells to recognize and kill their targets. All AgAbs (αCD20-, α CD19-, α CD21-and α CD22-3H10), induced target cell killing at amounts of both 10ng and 1ng (Fig. 3) . Furthermore, peptide alone induced target cell killing, while treatment with antibody containing no epitope produced cell lysis at levels equivalent to the media only control. Taken together, this data demonstrate that AgAb treatment of LCLs leads to antigen presentation to CD4+ T cells and T cell activation that results in directed T cell killing of the target LCLs.
Expression of B-cell markers and HLA molecules on B lymphoma cell lines
Since LCLs effectively present antigen, we next sought to investigate B lymphoma cell lines for their ability to present antigen to T cells. We obtained B lymphoma cell lines generated . 3 ), CD19, CD20, and CD22 (Suppl. Fig. 4 ) by FACS analysis. The CD21 receptor was expressed on the surface of all BL cell lines with the exception of DG75. In addition, expression of the CD19, CD20 and CD22 receptors was also detected on the surface of all of the BL cell lines (Suppl. Fig. 4) . We also performed FACS analysis to determine the level of HLA I and HLA II antigen expression on the surface of the BL cell lines to investigate their potential to present AgAb-targeted antigens to T cells (Suppl. 
B lymphoma cell lines efficiently present antigen targeted by AgAbs to CD4+ T cells
In order to investigate the propensity for BL cells to present antigen targeted by AgAbs to T cells, T cell response assays were performed using CD4+ T cell clones specific to epitopes from various EBV proteins and that matched the haplotypes of the BL cells (Fig. 4) . (Fig. 4) . However, in DG75 cells, only very low responses to AgAbs were observed. AgAbs were not as efficient in mediating However, the α CD21-AgAb was the least efficient of the AgAbs with regards to BL cell activation of T cells. In another example, the α CD22-AgAbs were 4300-, 430-430-and 4300-fold more effective than peptide alone in Awia, Yakobo, AG876, and DG75 cells, respectively. In the DG75 BL cells, we observed only low levels of T cell activation, but for the α CD21-B9 AgAb, we did not see any T cell responses, which is not surprising given the lack of CD21 on the surface of these cells (Suppl. Fig. 3 ). Interestingly, DG75 cells that were induced to express CD21 following stable transfection with a CD21 expression plasmid, could present antigen targeted via CD21 to CD4+ T cells (Suppl. Fig. 5 ).
Next we investigated whether CD4+ T cells activated by AgAbs containing the EBNA3C
3H10 epitope were capable of killing AG876 BL target cells (Fig. 5) . In an assay similar to the one performed using LCLs as the target cells (Fig. 3) , we used 51 Cr-release killing assays to determine cytotoxic activity. All AgAbs (αCD20-, α CD19-, α CD21-and α CD22-3H10), induced target cell killing at amounts of both 10ng and 1ng (Fig. 5 ).
These results suggest that treatment of BL cells with AgAbs can lead to the induction of a specific CD4+ T cell response and this results in a cytotoxic response against the BL cells.
This data highlights the potential of AgAb treatment as a therapy against B lymphoma, provided that these molecules can stimulate memory T cells specific for the antigen included in the AgAb.
AgAb can efficiently vehicle large protein segments into B-cells to induce their presentation.
The results obtained so far unequivocally demonstrated that EBV-immortalized B-cells or B-
cell lymphomas can efficiently present a well-characterized epitope cloned into an AgAb. However, only cells that express the suitable MHC class II haplotype would present this epitope. Therefore, we cloned increasingly larger portions (102bp, 300bp, 963bp) of the EBNA3C gene that includes the 5H11 peptide into the CD21-specific antibody to enlarge the panel of epitopes included in the AgAb and expand the size of the population that would recognize them. We then assessed the ability of these fusion proteins to generate a potent immune response using LCLs as antigen presenting cells and a T cell clone specific for 5H11.
To avoid steric hindrance within the carrier antibody, we introduced the viral antigens at the C-terminal end of the Ig protein. These AgAbs are very well expressed after transfection in 293 cells as shown in Fig 6. We successfully used three of the ex vivo expanded specific T cell clones to perform an IFN-γ release assay after pulsing the LCLs with the enlarged AgAbs. The result of a representative experiment with one of these clones is shown in Fig.6 .
We wished to extend these experiments to another large AgAb that comprises 600bp from EBNA1. This EBNA1 fragment contains a CD4-restricted epitope (3G2) and a CD8-restricted epitope (HPV) ( Table 1 ). This AgAb was expressed in 293 cells and used as an antigen source in an IFN-γ release assay with specific CD4 and CD8-restricted T cell clones. While the CD4-specific response was convincing, the signals generated by the CD8 epitope were at the limit of detection and difficult to interpret. Representative T cell assays interrogating both epitopes are shown in Suppl. Fig. 6 . These results confirm that the AgAb approach could be successfully adopted for the treatment of a large number of patients with diverse MHC haplotypes.
Ex vivo stimulation of CD4+ memory T cell clones
We then set out to determine the ability of the AgAbs to induce expansion and stimulate antigen-specific memory T cells. To that end, we incubated PBMC from an EBV-positive male donor with the 5H11-coupled CD21-specific AgAb. After 7 rounds of successive stimulation, we obtained 10 clones, 4 of which were tested in interferon gamma release assay using the α CD21 antibody armed with the 5H11 epitope. All T cell clones responded efficiently to this AgAb whilst there was no response against LCLs loaded with α CD21 native antibody or against untreated LCLs (Fig. 7 shows results for 2 clones). IFN-γ production by the T cell clones was still significant when LCLs were loaded with 10pg of the AgAb only.
All tested newly generated T cell clones showed an activation level comparable to the initially established 5H11 T cell line (Fig. 7) . We then attempted to directly reactivate peripheral These results provide solid evidence that AgAbs can reactivate circulating resting EBV-specific memory T cells and strongly increase the probability that this approach will elicit a potent T cell response in vivo. This underscores the power of these fusion proteins and suggests that they might even be more active in other lymphoma types.
Moreover, we were able to reactivate EBV-specific memory T cells ex vivo using PBMCs from an EBV-positive donor loaded with AgAbs fused with EBV epitopes. These results suggest that the AgAb will elicit an immune response against targeted tumor cells in vivo and highlight the potential of the AgAb strategy as a therapeutic option to stimulate B lymphomaspecific T cell responses in EBV seropositive patients. We have also shown that it is possible to incorporate large fragments of the viral proteins into the AgAbs. These contain multiple epitopes that will be recognized by a large number of MHC molecules. Therefore, it should be feasible to efficiently treat all individuals with a B-cell lymphoma with the AgAbs, independently of their MHC genotype.
CD19, CD20, CD21 and CD22 were efficiently targeted by AgAb treatment in our study.
Indeed, the cell surface expression of these molecules can vary between cell lines, and between lymphoma subtypes. In addition, relapse in lymphoma patients following treatment
with monoclonal antibodies such as rituximab has been associated with down-regulation of CD20 receptors. 9, 32 For these reasons, it may be advantageous to use a combination of and CD21 is expressed on both immature and mature B-cells. 33 Therefore, treatment with antibodies targeting these receptors will not result in permanent depletion of normal B-cells.
However, it is likely that there will be depletion of both normal and malignant B-cells expressing these receptors, although it is unlikely that this will occur at a greater extent than what is already observed with current monoclonal antibody-based therapies.
Most therapeutic approaches against cancer based on cytotoxic cells have used CD8+ cells.
However, cytotoxic CD4+ T cells are also extremely efficient at eliminating cells that present a specific antigen on MHC class II. 34 This fits with the observation that EBNA1-specific cytotoxic CD4+ are able to kill EBV+ BL cells. 35 Our work adds up to the evidence that the therapeutic potential of CD4+ cytotoxic cells warrants further investigation.
In summary, this study demonstrates that the potential of the AgAb strategy extends further than vaccination and that AgAbs could be used to stimulate CD4+ T cell responses specifically directed against B lymphoma cells and propose this approach as a novel therapeutic strategy. Conflict-of-interest disclosure: The authors declare no competing financial interests.
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